依达拉奉对急性脑梗死患者血清血管内皮生长因子和肿瘤坏死因子水平的影响

摘要

Objective To investigate Edaravone on the levels of serum vascular endothelial growth factor(VEGF) and tumor necrosis factor (TNF) -α in patients with acute cerebral infarction (ACI). Methods Eighty-four ACI patients were randomly divided into the Edaravone group and control group. On the basic of ACI routine treatment, Edaravone group received Edaravone 60 mg/d intravenous drip for 14 d. Pre and 14 d, 28 d post treatment, the neurological deficits of all the patients were evaluated by Scandinavian Stroke Scale (SSS) ; the levels of serum VEGF and TNF-ot were detected at 3 d,7 d and 14 d after onset, respectively by enzyme-linked immunosorbent assay. Results Compared with pre treatment, SSS of post treatment in the two groups were significantly decreased (P ＜ 0. 05 -0. 01), meanwhile, which in Edaravone group at each time point were significantly decrased than control group(all P ＜ 0. 05). The levels of serum VEGF and TNF-α at each time point in the two groups were significantly higher than normal values, and which at 7 d after onset were significantly higher than 3 d and 14 d after onset (all P ＜ 0. 05). The levels of serum VEGF at each time points in Edaravone group were significantly lower than the control group (all P ＜ 0. 01). The levels of serum TNF-α at each time point between the two groups were no statistical significance. Conclusion Edaravone can obviously decrease the levels of serum VEGF in ACI patients and reduce the brain damage caused free radical after ACI.%目的 探讨依达拉奉对急性脑梗死患者血清血管内皮生长因子(VEGF)和肿瘤坏死因子(TNF)-α水平的影响.方法 84例急性脑梗死患者随机分为依达拉奉组和对照组；在脑梗死常规治疗的基础上,依达拉奉组加用依达拉奉60 mg/d静脉滴注14 d.治疗前、治疗后14 d及28 d应用改良爱丁堡斯堪的那维亚量表( SSS)对患者进行临床神经功能缺损程度评分；应用酶联免疫吸附测定法检测患者发病3d、7d及14 d血清VEGF及TNF-α水平.结果 两组患者治疗14 d及28 d时SSS评分均较治疗前明显降低(P＜0.05 ～0.01),依达拉奉组各时间点SSS评分明显低于对照组(均P＜0.05).两组血清VEGF及TNF-α水平发病后各时间点较正常值明显增高,发病第7d时明显高于第3d和第14 d(均P＜0.05)；依达拉奉组各时间点血清VEGF水平明显低于对照组(均P＜0.01)；两组各时间点血清TNF-α水平差异无统计学意义.结论 依达拉奉可明显降低急性脑梗死患者血清VEGF水平,减轻脑梗死后自由基导致的脑损害.